Mandatory criteria include polyneuropathy, which is typically demyelinating, a monoclonal plasma cell-proliferative disorder, like Castleman disease or sclerotic plasmocytic bone lesions, and VEGF elevation.6 This evidence concerns the gene VEGFA and Castleman disease.